Thiamine supplementation modulates oxidative stress by inhibiting hepatic adenosine diphosphate (ADP)-ribosylation in obese diabetic rats

DOI Web Site 被引用文献2件 参考文献47件 オープンアクセス
  • Kohda Yuka
    Department of Pharmacotherapeutics, Osaka University of Pharmaceutical Sciences
  • Ueda Junpei
    Department of Pharmacotherapeutics, Osaka University of Pharmaceutical Sciences
  • Azuma Rie
    Department of Pharmacotherapeutics, Osaka University of Pharmaceutical Sciences
  • Nakatani Yuuka
    Department of Pharmacotherapeutics, Osaka University of Pharmaceutical Sciences
  • Murase Hiroto
    Department of Pharmacotherapeutics, Osaka University of Pharmaceutical Sciences
  • Matsui Kanta
    Department of Pharmacotherapeutics, Osaka University of Pharmaceutical Sciences
  • Takezoe Yuka
    Department of Pharmacotherapeutics, Osaka University of Pharmaceutical Sciences
  • Nagata Eiko
    Department of Pharmacotherapeutics, Osaka University of Pharmaceutical Sciences
  • Matsui Risa
    Department of Pharmacotherapeutics, Osaka University of Pharmaceutical Sciences
  • Tanaka Takao
    Department of Pharmacotherapeutics, Osaka University of Pharmaceutical Sciences
  • Matsumura Hitoshi
    Department of Pharmacotherapeutics, Osaka University of Pharmaceutical Sciences

この論文をさがす

説明

<p>Diabetic hyperglycemia is typically accompanied by various protein modifications, indicating hyperglycemic glucotoxicity. Overactivation of poly [adenosine diphosphate (ADP)-ribose] polymerase 1 (PARP-1) has been implicated in the pathogenesis of oxidative stress-related diseases including diabetes and its complications. Furthermore, obesity and diabetes are known to be associated with a substantial risk of chronic liver disease. We have previously reported that thiamine supplementation prevented obesity and diabetes-related liver disease. As a step forward, in the present study, we focus on hepatic ADP-ribosylation that reflects PARP-1 activation and an increased oxidative stress condition. Otsuka Long-Evans Tokushima Fatty (OLETF) rats were randomly divided into the following groups: thiamine-supplemented and unsupplemented control groups. The thiamine-supplemented group received 2 g of thiamine/L of drinking water for 33 weeks. ADP-ribosylated protein expression was analyzed in the livers of OLETF rats using Western blotting. Moreover, the fasting blood glucose level was measured in these rats. The obese diabetic OLETF rats exhibited high ADP-ribosylated protein expression in the liver. Interestingly, hepatic ADP-ribosylated protein expression and fasting blood glucose levels were lower in the thiamine-supplemented OLETF group than in the control OLETF group. These results suggest that thiamine supplementation attenuates oxidative stress by inhibiting hepatic ADP-ribosylation in OLETF rats. The beneficial effect of high-dose thiamine on oxidative stress-related diseases could be attributed to its inhibitory effect on PARP-1 activation, in addition to its role as a coenzyme. Furthermore, we found that thiamine supplementation prevented fasting hyperglycemia, suggesting that high-dose thiamine modifies the hepatic glucose metabolism and obesity-induced hepatic insulin resistance.</p>

収録刊行物

被引用文献 (2)*注記

もっと見る

参考文献 (47)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ